TRAILR3/TNFRSF10C Antibody (90903) [Unconjugated]

In the presence of the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (Catalog # 630-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (10 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R3/TNFRSF10C Monoclonal Antibody (Catalog # MAB630). The ND50 is typically 0.02-0.08 µg/mL.

• Reactivity: Hu
• Applications: B/N
• Clone: 90903
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

TRAILR3/TNFRSF10C Antibody (90903) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TRAIL R3/TNFRSF10C
  Ala26-Ala221
  Accession # O14798
• Specificity: Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots. In direct ELISAs, approximately 20%‑40% cross-reactivity with recombinant human (rh) TRAIL R1 is observed and no cross-reactivity with rhTRAIL R2 or rhTRAIL R4 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF10C
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.04-0.08 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TRAILR3/TNFRSF10C Antibody (90903) [Unconjugated]

• Antagonist decoy receptor for TRAIL/Apo-2L
• CD263 antigen
• CD263
• cytotoxic TRAIL receptor-3
• DcR1
• DCR1MGC149502
• Decoy receptor 1
• Decoy TRAIL receptor without death domain
• LITMGC149501
• Lymphocyte inhibitor of TRAIL
• TNFRSF10C
• TRAIL R3
• TRAIL receptor 3
• TRAIL receptor without an intracellular domain
• TRAILR3
• TRAIL-R3
• TRAILR3TNF-related apoptosis-inducing ligand receptor 3
• TRIDDCR1-TNFR
• tumor necrosis factor receptor superfamily member 10C
• tumor necrosis factor receptor superfamily, member 10c, decoy without anintracellular domain

Background

TRAIL R3, also called TNFRSF10C, DcR1 (decoy receptor 1), LIT, and TRID, is a glycosylphosphatidylinositol-linked membrane protein which binds TRAIL (Apo2 Ligand) with high affinity (1, 2). TRAIL R3 contains a TRAIL-binding extracellular cysteine-rich domain but lacks an intracellular signaling domain. As a result, binding of TRAIL to TRAIL R3 does not trigger a pro-apoptotic signal. TRAIL R3 has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis.

1. Sheridan, J.P. et al. (1997) Science 277:818.
2. Golstein, P. (1997) Curr. Biol. 7:R750.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRAILR3/TNFRSF10C Antibody (MAB630)(2)

Publications using MAB630

• Najib Ben Khaled, Katharina Hammer, Liangtao Ye, Ahmed Alnatsha, Sebastian A. Widholz, Ignazio Piseddu et al. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status Cancers (Basel) 2022-10-26 [PMID: 36358659]
• Najib Ben Khaled, Katharina Hammer, Liangtao Ye, Ahmed Alnatsha, Sebastian A. Widholz, Ignazio Piseddu et al. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status Cancers (Basel) 2022-10-26 [PMID: 36358659] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: TNFRSF10C
• Uniprot:
  • O14798()